Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZ-001 with Valganciclovir and Atezolizumab/Bevacizumab in HCC
NCT06695026Phase 2Recruiting
- Sponsor
- Rznomics
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of RZ-001 in hepatocellular carcinoma (HCC), sponsored by Rznomics. Started Dec 2024; status: recruiting.
02
Drugs
RZ-001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06695026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695026.